SEARCH

SEARCH BY CITATION

References

  • Agren H. and Lundqvist G. (1984) Low levels of somatostatin in human CSF mark depressive episodes. Psychoneuroendocrinology 9, 233248.
  • Banki C. M., Karmacsi L., Bissette G. and Nemeroff C. B. (1992) CSF corticotropin releasing hormone, somatostatin, and thyrotropin releasing hormone in schizophrenia. Psychiatry Res. 43, 1321.
  • Barnea A., Roberts J. and Ho R. H. (1999) Evidence for a synergistic effect of the HIV-1 envelope protein gp120 and brain-derived neurotrophic factor (BDNF) leading to enhanced expression of somatostatin neurons in aggregate cultures derived from the human fetal cortex. Brain Res. 815, 349357.
  • Beal M. F., Mazurek M., Tran V., Chattha G., Bird E. and Martin J. (1985) Reduced number of somatostatin receptors in cerebral cortex in Alzheimer’s disease. Science 229, 289291.
  • Beal M. F., Uhl G., Masurek M. F., Kowall N. and Martin J. B. (1986) Somatostatin: alterations in the central nervous system in neurological diseases, in Neuropeptide in Neurological and Psychiatric Disease (MartinJ. B. and MarchasJ. D., eds), pp. 215254. Raven Press, New York.
  • Beal M. F., Clevens R. A. and Mazurek M. F. (1988) Somatostatin and neuropeptide Y immunoreactivity in Parkinson’s disease dementia with Alzheimer’s changes. Synapse 2, 463467.
  • Bisette G., Cook L., Smith W., Dole K. C., Crain B. and Nemeroff C. B. (1998) Regional neuropeptide pathology in Alzheimer’s disease: corticotropin-releasing factor and somatostatin. J. Alzheimers Dis. 1, 91105.
  • Davies P., Katzman R. and Terry R. D. (1980) Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementia. Nature 288, 279280.
  • Davis K. L., Mohs R. C., Marin D. B., Purohit D. P., Perl D. P., Lantz M., Austin G. and Haroutunian V. (1999) Neuropeptide abnormalities in patients with early Alzheimer disease. Arch. Gen. Psychiatry 56, 981987.
  • Dawbarn D., DeQuidt M. E. and Emson P. C. (1985) Survival of basal ganglia neuropeptide Y–somatostatin neurons in Huntington’s disease. Brain Res. 340, 251260.
  • Dournaud P., Cervera-Pierot P., Hirsch E., Javoy-Agid F., Kordon C., Agid Y. and Epelbaum J. (1994) Somatostatin messenger RNA-containing neurons in Alzheimer’s disease: an in situ hybridization study in hippocampus, parahippocampal cortex and frontal cortex. Neuroscience 61, 755764.
  • Ferrante R. J., Kowall N. W., Beal M. F., Martin J. B., Bird E. D. and Richardson E. P. (1987) Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington’s disease. J. Neuropathol. Exp. Neurol. 46, 1227.
  • Forloni G., Lucca E., Angeretti N., Chiesa R. and Vezzani A. (1997) Neuroprotective effect of somatostatin on non-apoptotic NMDA-induced neuronal death: role of cyclic GMP. J. Neurochem. 68, 319327.
  • Geci C., Glinka Y., Kumar U. and Patel Y. C. (2000) Induction of somatostatin (SST) by β-amyloid peptide in cultured cortical neurons. Program Annual Meeting Society for Neuroscience, New Orleans, LA, November 4–9, 2000.
  • Gonzalez G. A., Yamamoto K. K., Fischer W. H., Karr D., Menzel P., Biggs W. III, Vale W. W. and Montminy M. R. (1989) A cluster of phosphorylation sites on the cyclic AMP-regulated nuclear factor CREB predicted by its sequence. Nature 337, 749752.
  • Grouselle D., Winsky-Sommerer R., David J. P., Delacourte A., Dournaud P. and Epelbaum J. (1998) Loss of somatostatin like immunoreactivity in the frontal cortex of Alzheimer patients carrying the apolipoprotein epsilon 4 allele. Neurosci. Lett. 255, 2124.
  • Ham J., Rickards C. and Scanlon M. (1991) Prolonged exposure to N-methyl-d-aspartate increases intracellular and secreted somatostatin in rat cortical cells. Neurosci. Lett. 129, 262264.
  • Ham J., Duberley R., Rickards C. and Scanlon S. (1993) Differential responses of rat cerebral somatostatinergic and cholinergic cells to glutamate agonists. Mol. Chem. Neuropathol. 19, 107120.
  • Hayashi M., Yamashita A. and Shimizu K. (1997) Somatostatin and brain derived neurotrophic factor mRNA expression in the primate brain: decreased levels of mRNA during aging. Brain Res. 749, 283289.
  • Koutkia P., Meininger G., Canavan B., Breu J. and Grinspoon S. (2004) Metabolic regulation of growth hormone by free fatty acids, somatostatin, and ghrelin in HIV-lipodystrophy. Am. J. Physiol. Endocrinol. Metab. 286, E296E303.
  • Krantic S., Robitaille Y. and Quirion R. (1992) Deficits in the somatostatin SS1 receptor subtype in frontal and temporal cortices in Alzheimer’s disease. Brain Res. 573, 299304.
  • Kumar U. (2004) Characterization of striatal cultured neurons in QUIN and NMDA induced toxicity. Neurosci. Res. 49, 2938.
  • Kumar U. (2005) Expression of somatostatin receptor subtypes (SSTR1–5) in Alzheimer’s disease (AD) brain: an immunohistochemical analysis. Neuroscience 134, 525538.
  • Kumar U., Asotra K., Patel S. C. and Patel Y. C. (1997) Expression of NMDA receptor 1 (NR1) and Huntington in striatal neurons which co-localize somatostatin, neuropeptide Y, and NADPH diaphorase: a double-label histochemical and immunohistochemical study. Exp. Neurol. 145, 412424.
  • Lorenzo A. and Yankner B. A. (1994) Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Natl Acad. Sci. USA 91, 12 24312 247.
  • Lu T., Pan Y., YuanKao S., Li C., Kohane I., Chan J. and Yanker B. A. (2004) Gene regulation and DNA damage in the ageing human brain. Nature 429, 883891.
  • Lynch C. and Mobley W. (2000) Comprehensive theory of Alzheimer’s disease. The effects of cholesterol on membrane receptor trafficking. Ann. N. Y. Acad. Sci. 924, 104111.
  • Nemeroff C. B. (1999) The preeminent role of neuropeptide systems in the early pathophysiology of Alzheimer’s disease: up with corticotropin-releasing factor, down with acetylcholine. Arch. Gen. Psychiatry 56, 991992.
  • Patel S. C., Papachristou D. N. and Patel Y. C. (1991) Quinolinic acid stimulates somatostatin gene expression in cultured rat cortical neurons. J. Neurochem. 56, 12861291.
  • Patel Y. C., Liu J. L., Warszynska A., Kent G., Papachristou D. N. and Patel S. C. (1995) Differential stimulation of somatostatin but not neuropeptide Y gene expression by quinolinic acid in cultured cortical neurons. J. Neurochem. 65, 9981006.
  • Rage F., Rougeot C. and Tapia-Arancibia L. (1994) GABAA and NMDA receptor activation controls somatostatin messenger RNA expression in primary cultures of hypothalamic neurons. Neuroendocrinology 60, 470476.
  • Reichlin S. (1983) Somatostatin. N. Engl. J. Med. 309, 14951501.
  • Sato T., Iwata N., Tsubuki S., Takaki Y., Takano J., Huang S. M., Suemoto T., Higuchi M. and Saido T. C. (2004) Somatostatin regulates brain amyloid B peptide AB42 through modulation of proteolytic degradation. Nat. Med. 11, 434439.
  • Tapia-Arancibia L. and Astier H. (1989) Actions of excitatory amino-acids on somatostatin release from cortical neurons in primary cultures. J. Neurochem. 53, 11341141.
  • Vecsei L., Csala B., Widerlov E., Ekman R., Czopf J. and Palffy G. (1990) Lumbar cerebrospinal fluid concentrations of somatostatin and neuropeptide Y in multiple sclerosis. Brain Res. Bull. 25, 411413.
  • Williams J. S., Berbekar I. and Weiss S. (1991) N-Methyl-d-aspartate evokes the release of somatostatin from striatal interneurons in primary culture. Neuroscience 43, 437444.
  • Wood P. L., Etienne P., Lal S., Gauthier S., Cajal S. and Nair N. P. (1982) Reduced lumbar CSF somatostatin levels in Alzheimer’s disease. Life Sci. 31, 20732079.
  • Yankner B. A., Duffy L. K. and Kirshner D. A. (1990) Neurotrophic and neurotoxic effects of amyloid β protein: reversal by tachykinin neuropeptides. Science 250, 279282.